Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.